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ABSTRACT LysPE40 is a modified form of Pseudomonas
exotoxin that lacks the cell-binding domain and has a chemi-
cally reactive lysine residue near the amino terminus. LysPE40
is made in Escherichia coli and secreted into the medium from
which it is readily purified. Two immunotoxins were con-
structed by coupling LysPE40 to an antibody to the human
transferrin receptor (TFR) or to an antibody to the human
interleukin-2 receptor. These immunotoxins were selectively
cytotoxic to receptor-bearing cells in tissue culture. Anti-
TFR-LysPE40 given intraperitoneally to mice appeared rap-
idly in the blood and caused regression ofA431 tumors growing
as subcutaneous xenografts. These results show that it is
possible to cause regression of a solid carcinoma by an immu-
notoxin if proper targeting can be achieved.
One new approach to cancer treatment that has received
considerable attention in the past few years is to direct
cytotoxic agents to cancer cells by using tumor-specific
antibodies (1, 2). Cytotoxic molecules delivered by this
method include bacterial and plant toxins, conventional
chemotherapeutic agents such as adriamycin and methotrex-
ate, and radioisotopes (1, 3-5). We have been investigating
the utility of immunotoxins in which antibodies are attached
to Pseudomonas exotoxin (PE). In early studies, we coupled
native PE to an antibody specific for the human transferrin
receptor (TFR) and showed that this type of conjugate
(anti-TFR-PE) selectively killed human cancer cells in tissue
culture (6). It was then tested in mice and, when given i.p.,
was shown to greatly prolong the survival of mice with a
lethal human ovarian cancer growing in their peritoneal
cavity (7). However, anti-TFR-PE was not effective when
administered either i.v. or when given i.p. to animals with
subcutaneous tumors because liver damage produced by the
immunotoxin limited the amount of drug that could be given.
Only by giving the immunotoxin into the same body com-
partment as the tumor could tumor cells be killed without
unacceptable side effects. Subsequently, PE was attached to
the monoclonal antibody OVB3, which specifically binds to
human ovarian cancer cells. This immunotoxin (OVB3-PE)
has been shown to kill human ovarian cancer cells in cell
culture, prolong the life of nude mice bearing a lethal human
ovarian tumor (8), and is currently in a clinical trial. How-
ever, OVB3-PE, like anti-TFR-PE, is effective primarily
when given i.p. against i.p. tumors (8).
PE is a Mr 66,000 single-chain protein that is composed of
three domains (9). The liver toxicity and toxicity to other cell
types produced by immunotoxins made with native PE are
principally due to the binding of domain I of PE to liver cells
(unpublished observations). Various recombinant forms of
PE have been made in Escherichia coli, including one with a
Mr of40,000 (PE40) that lacks domain I and has very low liver
toxicity because it no longer binds to the PE receptor present
on liver cells. PE40 was chemically coupled to several
antibodies, including one that reacts with the human TFR
(10). The anti-TFR-PE40 conjugate had the expected de-
crease in liver toxicity, but unexpectedly it was also much
less active than anti-TFR-PE against human cells containing
TFR (10). In searching for an explanation for this loss of
activity, we noted that PE40 was poorly reactive with the
heterobifunctional cross-linking reagent succinimidyl 4-
(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)
used to make the immunotoxin. A 25-fold excess of cross-
linker was needed to derivatize half of the PE40 molecules.
Also we noted that the three "target" lysine residues were
located at the carboxyl end of PE40.
The current paper describes the properties of a modified
form of PE40 termed LysPE40 in which a lysine molecule is
included near the amino end. This molecule is readily coupled
to antibodies. The immunotoxin produced by coupling
LysPE40 to anti-TFR (anti-TFR-LysPE40) has low nonspe-
cific toxicity in mice, so that high blood levels can be
obtained. Furthermore, anti-TFR-LysPE40 injected i.p.
caused complete regression of small subcutaneous tumors
and very marked destruction of large subcutaneous tumors.
These experiments show that, if proper targeting can be
achieved, an immunotoxin containing LysPE40 can have
striking therapeutic effects on a rapidly growing solid carci-
noma.
MATERIALS AND METHODS
Bacterial Strains and Plasmids. Bacterial strains HB101 and
BL21 (ADE3) have been described (11). The plasmid pJY85L
was made from pVC45 (12), codons for amino acids 6-251
were deleted, and glutamic acid at position 252 was changed
to lysine by site-directed mutagenesis.
Expression of LysPE40. BL21 (ADE3) cells were trans-
formed with plasmid pJY85L and grown in LB medium
containing 100 ,ug of ampicillin per ml at 37°C. At A650 = 0.6,
isopropyl 1-thio-,8-D-galactopyranoside was added to a final
concentration of 1 mM. Cells were harvested 90 min later.
The culture medium was used as the source of LysPE40
because most of the protein was secreted into the medium.
Purification of LysPE40. Twenty-five liters of clarified
culture medium containing LysPE40 was diluted 1:4 with
chilled deionized water and applied to a 10 x 5.5 cm silica-
based anion-exchange column (QMA, Waters) at a flow rate
of 100 ml/min. The column was washed with 0.05 M sodium
Abbreviations: PE, Pseudomonas exotoxin; TFR, transferrin recep-
tor; SMCC, succinimidyl 4-(N-maleimidomethyl)cyclohexane-
1-carboxylate; IL-2, interleukin-2.
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phosphate buffer (pH 7.0), and proteins were eluted with 2
liters of 0.25 M NaCl in the equilibration buffer. LysPE40
from the QMA column was concentrated further by using
Amicon YM30 membranes to 150 ml, dialyzed for 12-16 hr
against 0.02 M Tris HCl (pH 7.6), centrifuged at 10,000 x g
for 20 min, and applied to a 2.5 x 14 cm Q-Sepharose column
equilibrated with 0.02 M Tris HCl (pH 7.6). Proteins were
eluted with a 500-ml linear gradient of 0-0.5 M NaCl;
LysPE40-containing fractions were detected by sodium do-
decyl sulfate/polyacrylamide gel electrophoresis (SDS/
PAGE), pooled, diluted 1:10 with 0.02 M Mes (pH 5.5), and
loaded onto a fast protein liquid chromatography (FPLC)
Mono S 16/10 column equilibrated with 0.02 M Mes (pH 5.5).
LysPE40 bound to the column and was eluted by a 100-ml
linear gradient of 0-0.5 M NaCl. It was further purified on
TSK250 (22.5 x 600 mm) column (Bio-Rad) with 0.2 M
sodium phosphate (pH 7.0) containing 1 mM EDTA.
Construction ofImmunoconjugates. LysPE40 (5-10 mg/ml)
in 0.2 M sodium phosphate (pH 7.0) containing 1 mM EDTA
was mixed with a 3-fold molar excess ofSMCC and incubated
at room temperature for 30 min. Protein was separated from
the unreacted cross-linker on a PD10 column. Monoclonal
antibody (HB21, anti-Tac, MOPC 21) (5-10 mg/ml) was
mixed with a 3-fold molar excess of 2-iminothiolane HCI in
0.2 M sodium phosphate (pH 8.0) containing 1 mM EDTA
and incubated at 37°C for 1 hr. The derivatized antibody was
separated from the reactants on a PD10 column. Derivatized
LysPE40 and derivatized antibody were mixed in a 4:1 molar
ratio and incubated at room temperature for 16-20 hr. Im-
munotoxin was then purified by successive chromatography
on Mono Q and TSK 250 columns (10). Immunotoxins were
also made with PE as described (10). SDS/PAGE was done
as described (10).
Protein Synthesis-Inhibition Assay. Activities of the conju-
gates were tested on A431, KB, HUT 102, HT29, OVCAR-2,
OVCAR-3, OVCAR-4, CEM, and MOLT4 cells by measur-
ing [3H]leucine incorporation (10). HUT 102 cells were
washed twice with RPM 1640 and used immediately. Immu-
notoxins were diluted with 0.2% human serum albumin in
phosphate-buffered saline prior to addition to cells.
Assay of Blood Levels of Anti-TFR-LysPE40 in Mice. Fe-
male BALB/c mice or immunodeficient (nu/nu) mice bearing
A431 subcutaneous tumors were injected with 100 ,ug or 50 ,ug
of immunotoxin i.p. Blood was drawn at different times, and
the level of the immunotoxin was assayed by incubating
serum with A431 cells and measuring its effect on protein
synthesis. A standard curve was made with anti-TFR-
LysPE40.
Antitumor Activity of Anti-TFR-LysPE40 in Nude Mice
Bearing a Human Epidermoid Carcinoma. A431 cells (3 x 106)
were injected subcutaneously on day 0 into female nude
mice, and tumors about 5 x 5 mm in size developed in all mice
by day 5. Treatment of mice was started either 2 days, 5 days,
or 9 days after tumor implantation. Each treatment group
consisted of four to six animals. Tumors were measured with
a caliper every fourth day, and the volume of the tumor was
calculated by using the formula: tumor volume in mm3 =
length x (width)2 x 0.4.
RESULTS
Previously, we described the properties of immunotoxins
made with PE40. The activities of these immunotoxins were
lower than anticipated, and the yields were poor (10). Cross-
linking ofthe toxin appeared to be through one of three lysine
residues present at the carboxyl end of PE40, which were
poorly reactive with SMCC or similar heterobifunctional
cross-linking reagents used in the construction of immuno-
toxins (10). In contrast, native PE is readily conjugated to
antibodies. Since in native PE there are 12 lysine residues in
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FIG. 1. Structure of plasmid pJY85L showing the presence of a
phage T7 promoter, an OmpA signal sequence, and domains 11
(translocation domain) and III (ADP ribosylation domain) of PE.
domain I, some of which are very reactive with SMCC, we
thought a useful immunotoxin could be made by modifying
PE40 so that conjugation would proceed through a readily
accessible lysine residue that did not' play an important role
in the activity of the protein. To accomplish this, the amino
end of PE40 was altered so that it contained a lysine residue
and an OmpA signal sequence. The OmpA signal sequence
was added to direct the export of LysPE40 to the growth
medium. The structure ofLysPE40 and the plasmid encoding
LysPE40, which is under the control of a phage T7 promoter,
is shown in Fig. 1. LysPE40 is secreted into the culture
medium in large amounts.
The purification of LysPE40 is described in Materials and
Methods. The purity of the protein at each purification step
is shown in Fig. 2A. Material from the TSK 250 column,
which was used as the final step, appeared to be homoge-
neous when analyzed by SDS/PAGE (Fig. 2A, lane 5) as well
as by immunoblotting with an antibody to PE (data not
shown). Typically, 2-3 mg of pure LysPE40 was obtained
from 1 liter of culture induced at an absorbance at 650 nm of
0.6.
The amino-terminal sequence of the purified protein was
found to be Ala-Asn-Leu-Ala-Glu-Glu-Ala-Phe-Lys-Gly-
Gly-Ser-Leu. This is the amino acid sequence expected from
the DNA sequence with processing occurring within the
OmpA sequence (Fig. 1). The amino-terminal sequence of
PE40 is Ala-Asn-Leu-Ala-Glu-Glu-Gly-Gly (10).
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FIG. 2. (A) SDS/PAGE analysis of LysPE40 pools at various
stages of purification; 12.5% gels were stained with Coomassie blue.
Lanes: 1, QMA-concentrated culture medium proteins; 2, Q-
Sepharose pool; 3, flow-through material from Mono S; 4, Mono S
pool; 5, TSK 250 pool. The positions of molecular weight standards
are indicated in kDa. (B) SDS/PAGE analysis ofanti-TFR-LysPE40.
Samples were applied on a 12.5% reducing polyacrylamide gel.
Lanes: 1, anti-TFR-LysPE40 conjugate, with heavy chain (a) and
light chain (b); 2, LysPE40; 3, anti-TFR. Gels were stained with
Coomassie blue.
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Table 1. Activity of anti-TFR-LysPE40 on various human
cell lines
ID50*, ng/ml
Cells Anti-TFR-LysPE40 LysPE40
A431 4.0 >2000
KB 14.0 >2000
HT29 6.6 >2000
HUT 102 21.0 >2000
CEM 22.5 >2000
OVCAR-2 135.0 ND
OVCAR-3 280.0 ND
OVCAR-4 30.0 ND
MOLT-4 32.0 ND
*ID50 is described as the concentration of the immunotoxin needed
for 50o inhibition of protein synthesis. ND, not done.
Construction ofImmunotoxins with LysPE40. LysPE40 was
chemically coupled to two different monoclonal antibodies-
HB21, which binds to the human TFR (anti-TFR) (13), and
anti-Tac, which binds to the 55-kDa subunit of human inter-
leukin-2 (IL-2) receptor (14). After the conjugation, the
immunotoxins were purified on Mono Q and TSK 250 col-
umns. Purified conjugates were found to contain LysPE40
coupled to both the light and heavy chain of the antibody and
did not contain any free LysPE40 (Fig. 2B, lane 1).
Activity of Immunotoxins Made with LysPE40. The activity
of anti-TFR-LysPE40 was assayed on a variety of human cell
lines; it inhibited protein synthesis in all ofthe human cell lines
studied (Table 1). Anti-TFR-LysPE40 was most active on
A431 cells with an ID50 of 4.0 ng/ml. Specificity was demon-
strated by showing that excess unconjugated antibody pre-
vented the cytotoxic effect of anti-TFR-LysPE40 (Fig. 3A).
Anti-TFR-LysPE40 was not cytotoxic to murine Swiss 3T3
cells even at 2 ,tg/ml (data not shown).
To determine if LysPE40 could be coupled to other anti-
bodies to yield an active conjugate, the anti-Tac antibody was
chosen. This antibody reacts with the p55 subunit of the IL-2
receptor. The cytotoxic activity of anti-Tac-LysPE40 was
determined on HUT 102 cells, a human T-cell leukemia line
containing IL-2 receptors. Anti-Tac-LysPE40 inhibited pro-
tein synthesis in HUT 102 cells with an ID50 of 2.5 ng/ml, and
excess anti-Tac blocked this effect, demonstrating the spec-
ificity of the immunotoxin (Fig. 3B). Anti-Tac-LysPE40 did
not inhibit protein synthesis on IL-2 receptor-negative cells,
e.g., CEM and KB, even at 2000 ng/ml, further showing the
specificity of the immunotoxin.
Blood Levels of Anti-TFR-LysPE40 in Mice. BALB/c mice
were injected i.p. with a single dose of 100 jig of anti-
TFR-LysPE40, and blood was drawn at different times after
the injection to assay for immunotoxin activity. A peak blood
level of 78 gg/ml was obtained 4 hr after the injection, and a
level of 10 jug/ml was still present 24 hr after the injection
(Fig. 4). A similar experiment was performed in athymic mice
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FIG. 4. Blood levels of anti-TFR-LysPE40. BALB/c mice (m) or
nude mice with A431 tumors (e) were injected i.p. with 100 ,ug or 50 ,ug
of anti-TFR-LysPE40. Immunotoxin levels were measured in serum at
different time periods. Results are the average of two experiments.
bearing A431 tumors. After injecting 50 ,ug of anti-TFR-
LysPE40, a blood level of 27 pug/ml was detected 4 hr after
injection and 8 ,ug/ml after 24 hr (Fig. 4).
Antitumor Activity of Anti-TFR-LysPE40. Anti-TFR-
LysPE40 was assayed for its ability to inhibit the growth of
A431 cells as subcutaneous xenografts in nude mice. To
produce tumors, 3 x 106 A431 cells were injected subcuta-
neously on day 0. In the control group, treated only with
diluent, the tumors grew rapidly, and the animals were
sacrificed on day 19 with large tumors that were penetrating
the skin. (Figs. 5 and 6). In a group that received anti-
TFR-LysPE40 (50 ,ug per injection) on days 2, 4, 6, and 8, no
tumors were evident on day 24 when the experiment was
terminated (Figs. SA and 6). In another group of animals,
treatment was delayed until the tumors were about 125 mm3
in volume and was given on days 9, 11, 13, and 15. As soon
as the treatment was initiated, the tumors stopped increasing
in size (Figs. 5A and 6) and then developed soft centers.
Histological examination showed that almost all of the cells
in the center of the tumor were nonviable (Fig. 7). However,
at the rim of the tumor, viable cells were observed.
To determine if the antitumor effect was dose-related,
treatment with various amounts of anti-TFR-LysPE40 was
begun on day 5, when small tumors were evident (Fig. SB).
Even the 5-,ug dose produced a delay in tumor growth, but
after the treatment was stopped on day 11, the tumors began
to grow rapidly. As the dose was increased to 20 or 50 ,ug, some
or all of the tumors became undetectable by day 11. However,
with time, some tumors began to reappear and grow (Table 2).
One group ofanimals received a single dose on day 5 of 150 Ag,
which is close to the LD50. Two animals died, but in the other
three animals the tumor regressed and did not reappear (Table
FIG. 3. (A) Inhibition of protein syn-
thesis in A431 cells by anti-TFR-
LysPE40. Immunotoxin was added to the
cells in the absence (e) and presence (0)
of excess anti-TFR (50 ,ug/ml) for 18-24
hr at 370C. (B) Cytotoxic activity of anti-
Tac-LysPE40 on HUT 102 cells. Anti-
Tac-LysPE4O was added at various con-
centrations to HUT 102 (e), CEM (W),
and KB (o) cells. For the competition
experiment, 70 Ag of anti-Tac per ml was
added before the addition of the immu-
notoxin to HUT 102 cells (o). [3H]Leu-cine incorporation was measured as
described.
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FIG. 5. Effect of anti-TFR-LysPE40 on
the growth of A431 tumors in nude mice.
Mice were injected with 3 x 106 A431 cells
and treated i.p. with the immunotoxin as
indicated. (A) Mice were given four doses of
50 ,g each on days 2, 4, 6, and 8 (e), or on
days 9, 11, 13, and 15 (A) or were given no
treatment (A). (B) Mice were given no treat-
ment (A) or were given four doses on days 5,
7, 9, and 11 of 5 Iug (E), 20 /ig (A), or 50 ,tg
(A) or a single dose of 150 ,tg on day 5 (A).
2). When antibody alone or an immunotoxin composed of an
antibody that did not react with the tumor (MOPC21-
LysPE40) was administered at the 50-pg dose level, an anti-
tumor response was not observed (data not shown).
DISCUSSION
We describe here a modified form ofPE termed LysPE40 that
can be efficiently coupled to antibodies yielding an immuno-
I
FIG. 6. Gross appearance of subcutaneous A431 tumors in nude
mice with and without treatment with anti-TFR-LysPE40. Nude
mice were injected subcutaneously with 3 x 106 A431 cells on day 0.
The tumors were apparent as small bumps under the skin on day 5
(arrows in A), and by day 15 tumors were large, often erupting
through the skin surface (B). Mice treated with anti-TFR-LysPE40 on
days 2, 4, 6, and 8 usually showed no development of tumor,
demonstrated here as the absence ofgross tumor on day 26 (C). When
mice with large tumors were treated with anti-TFR-LysPE40 (on
days 9, 11, 13, and 15), the tumors began to shrink, collapsing inward
on their necrotic centers (arrows in D).
toxin with high cytotoxic activity against cultured cell lines
bearing the appropriate antigen and no detectable cytotox-
icity against cultured cells to which the antibody does not
bind. Furthermore, an immunotoxin composed of an anti-
body to the human TFR coupled to LysPE40 (anti-
TFR-LysPE40) could be administered safely in large amounts
to mice and caused regression of a rapidly growing human
epidermoid carcinoma implanted subcutaneously.
When administered i.p. in mice, anti-TFR-LysPE40 ap-
peared rapidly in the blood. A dose of 50 ,ug gave a peak blood
level 4 hr after injection of about 30 Ag/ml, and blood levels
were still 8 ug/ml at 24 hr (Fig. 4), indicating that this
immunotoxin has a relatively long half-life. A single dose of
100 ,ug gave a peak blood level of80 gg/ml. Since a 20-g mouse
has a blood volume of about 1 ml, almost all of the immuno-
toxin is found in the blood 4 hr after i.p. administration.
In most of the treatment protocols used in this study, the
tumor cells were allowed to grow to form a detectable solid
tumor before treatment was initiated. Under these conditions,
a treatment consisting of four injections given over 8 days
caused obvious tumor regression (Figs. 5-7). At the lower
dose levels with small tumors, or even at the high dose level
with large tumors, viable tumor cells remained. Perhaps by
continuing the treatment for longer periods, a larger antitumor
effect could be achieved. Nevertheless, we have been able to
cause marked regression by an immunotoxin of a solid cancer
that is resistant to standard chemotherapy.
Several investigators have reported partial suppression of
tumor growth in various animal models by specific immuno-
toxins made with ricin A chain (15, 16), diphtheria toxin A chain
(17), or gelonin (18). In most of these studies, the in vivo
cytotoxic effect was observed when the treatment was started
on the same day or 1 day after the tumor implantation. Immu-
notoxins made with ricinA chain are rapidly eliminated from the
blood. The clearance of i.v.-injected immunotoxins has been
shown to be biphasic, with an initial rapid a phase followed by
Table 2. Incidence of tumors in nude mice treated with
anti-TFR-LysPE40
Animals on postinjection day,
no. with tumors/no. injected
Anti-TFR-LysPE40 11 15 19 24 29 35
None 5/5 5/5 5/5 - -
5 g 5/6 6/6 6/6 6/6 6/6
20,ug 1/5 1/5 3/5 3/5 3/5 4/5
50,ug 0/5 0/5 1/5 1/5 1/5 2/5
150 gg* 0/3 0/3 0/3 0/3 0/3 0/3
Athymic mice were injected subcutaneously with 3 x 106 A431
cells. On days 5, 7, 9, and 11, the animals were injected i.p. with
anti-TFR-LysPE40 at the indicated dose. The number of animals
with tumors/total animals injected is shown on different days after
tumor transplantation.
*Single dose on day 5. Two animals died on day 7.
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FIG. 7. Histological appearance of typical treated and control A431 subcutaneous tumors. A431 tumors were removed, fixed in
formaldehyde, and processed for routine paraffin embedding and sectioning and staining with hematoxylin and eosin. (A) A section from a tumor
removed from a mouse at day 15. (B) A similar section of a tumor removed from a mouse on day 19 that had been treated on days 9, 11, 13,
and 15 with anti-TFR-LysPE40. A shows that the majority of the untreated tumor contains viable tumor cells (VT) with only small areas of
necrosis (arrow). B shows that a large percentage of the treated tumor is necrotic (NT), with only a small rim of viable tumor (VT) remaining
(s = skin). (A', A" and B', B") Higher magnification fields from the margins of tumors. The untreated tumor is mostly composed of homogeneous
viable tumor cells (VT), whereas the treated tumor shows a rim of viable cells of variable thickness lying adjacent to a connective tissue capsule
(ct). (A and B = x3, Bar = 1 mm; A' and B' = x17, Bar = 200 ,um; A" and B" = x170; Bar = 20 /im).
a slower f phase (19, 20). An immunotoxin made with anti-
epidermal growth factor receptor and ricin A (528-rRA) has
been shown to inhibit growth of A431 xenografts in nude mice
when the treatment is started at the time of tumor implantation
(16). The peak blood level of only 3.2% of injected conjugate
was achieved 6 hr after the i.p. injection (16).
The current reagent, anti-TFR-LysPE40, is probably not
useful for human studies because transferrin receptors are
present on important normal tissues. Therefore, LysPE40 will
need to be attached to antibodies like anti-Tac that bind antigen
that are less widely distributed on normal cells to determine if
any ofthese molecules can be developed into useful therapeutic
agents.
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